Rheumatic Disorders

  • Neil Cardoe

Abstract

The rheumatic group of disorders represents over 200 different clinical entities. These diseases affect the musculoskeletal system, a system made up not only of joints but also of the tissues acting on, supporting or surrounding the joints. The three main components are (1) the synovium, which lines the joint and is responsible for its nutrition and for the secretion of joint fluid (which lubricates the joint and separates the joint surfaces), (2) the cartilage, which acts as a cushion between the joint surfaces, and (3) the tissues that act on the joint (i.e. the muscles, tendons and their sheaths), and the stabilizing mechanism of the joint, the ligaments and capsule. Any one of these tissues may be involved in the disease process, and, because there is considerable overlap in the function of the tissues involved, classification is difficult.

Keywords

Corticosteroid Osteoarthritis Psoriasis Proteinuria Acne 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Emery P, Salmon M. Early rheumatoid arthritis; time to aim for remission. Ann Rheum Dis 1995; 54: 944–7.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Emery P et al. Genetically determined factors as predictors of radiological change in patients with early symmetrical arthritis. BMJ 1992; 305; 1387–9.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Young A et alArthritis rheum 1991; 34(9); 483.Google Scholar
  4. 4.
    Pincus T. Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 1988; 41; 1037–41.CrossRefPubMedGoogle Scholar
  5. 5.
    Horneff G et al. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 1991; 34; 129–40.CrossRefPubMedGoogle Scholar
  6. 6.
    Jorizzoo JL, Rogers RS. Behcet’s disease. J Am Acad Dermatol 1990; 23; 738–41.CrossRefGoogle Scholar
  7. 7.
    Brauneis J et al. Long-term study of patients with severe forms of Sjøgren syndrome and/or myoepithelial sialadenitis. Laryngorhinootologie 1989; 68; 442–4.CrossRefPubMedGoogle Scholar
  8. 8.
    Chevallard M et al. Efficacy and tolerability of galactosamino-glycuronglycan sulfate in osteoarthritis of the knee; an 11 month experience. J Clin Pharmacol Res 1993; 13, supp P; 49–53.Google Scholar
  9. 9.
    Jones AC, Doherty M. The treatment of osteoarthritis. Br J Clin Pharmacol 1992; 33; 357–63.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Seagroatt V et al. Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. BMJ 1991; 303: 1431–5.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Tan EM et al. The revised criteria for the classification of SLE. Arthritis Rheum 1982; 25; 1271–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Shulman LE. Diffuse fasciitis with hyper-globulinemia and eosinophilia: a new syndrome? (abstract). J Rheumatol 1974; 1 (suppl.): 46.Google Scholar
  13. 13.
    Jones JG, Hazelman BL. Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis 1981; 40; 1–5.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Center for Disease Control. Eosinophilia-myalgia syndrome—New Mexico. MMWR; Nov 17, 1989; 765–7.Google Scholar
  15. 15.
    Curtin SM, Pennington TH. The diagnosis of Lyme disease. J R Soc Med 1995; 88; 248–50.PubMedCentralPubMedGoogle Scholar

Copyright information

© Palgrave Macmillan, a division of Macmillan Publishers Limited 2000

Authors and Affiliations

  • Neil Cardoe

There are no affiliations available

Personalised recommendations